These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27871332)

  • 41. An insight into the deep web; why it matters for addiction psychiatry?
    Orsolini L; Papanti D; Corkery J; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The interest in eight new psychoactive substances before and after scheduling.
    Ledberg A
    Drug Alcohol Depend; 2015 Jul; 152():73-8. PubMed ID: 25981311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of 'legal high' packages containing synthetic cathinones.
    Araújo AM; Valente MJ; Carvalho M; Dias da Silva D; Gaspar H; Carvalho F; de Lourdes Bastos M; Guedes de Pinho P
    Arch Toxicol; 2015 May; 89(5):757-71. PubMed ID: 24903018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review.
    Orsolini L; Chiappini S; Corkery JM; Guirguis A; Papanti D; Schifano F
    Expert Rev Neurother; 2019 Dec; 19(12):1253-1264. PubMed ID: 31503507
    [No Abstract]   [Full Text] [Related]  

  • 45. Phantom menace: novel psychoactive substances and the UK Armed Forces.
    Hunter AH; Ayres T; Moreland N; Cox A
    J R Army Med Corps; 2018 Nov; 164(6):450-457. PubMed ID: 29934414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
    Palamar JJ; Martins SS; Su MK; Ompad DC
    Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psychotropic medication non-adherence and associated factors among adult patients with major psychiatric disorders: a protocol for a systematic review.
    Semahegn A; Torpey K; Manu A; Assefa N; Tesfaye G; Ankomah A
    Syst Rev; 2018 Jan; 7(1):10. PubMed ID: 29357926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. "Someone Else's Problem": New Psychoactive Substances in the Online Hungarian Media.
    Kassai S; Rácz J; Nagy A; Bíbók T; Galambvári É; Kilián C; Gyarmathy VA
    J Psychoactive Drugs; 2017; 49(1):47-51. PubMed ID: 28010181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations.
    Soussan C; Kjellgren A
    Int J Drug Policy; 2016 Jun; 32():77-84. PubMed ID: 27184218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Do police arrestees substitute legal highs for other drugs?
    Wilkins C; Parker K; Prasad J; Jawalkar S
    Int J Drug Policy; 2016 May; 31():74-9. PubMed ID: 26948501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A market on both "sides" of the law: The use of the hidden web for the sale of new psychoactive substances.
    Wadsworth E; Drummond C; Kimergård A; Deluca P
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28617997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phencyclidine-Based New Psychoactive Substances.
    Wallach J; Brandt SD
    Handb Exp Pharmacol; 2018; 252():261-303. PubMed ID: 30105474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products.
    Zamengo L; Frison G; Bettin C; Sciarrone R
    Toxicol Lett; 2014 Aug; 229(1):220-8. PubMed ID: 24910986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New psychoactive substances legislation in Ireland - Perspectives from academia.
    Kavanagh PV; Power JD
    Drug Test Anal; 2014; 6(7-8):884-91. PubMed ID: 24478277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deconstructing Designer Drugs.
    Sellers EM
    Clin Pharmacol Ther; 2017 Feb; 101(2):167-169. PubMed ID: 27564430
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Synthetic Drugs - An Overview of Important and Newly Emerging Substances].
    Betzler F; Heinz A; Köhler S
    Fortschr Neurol Psychiatr; 2016 Nov; 84(11):690-698. PubMed ID: 27846654
    [No Abstract]   [Full Text] [Related]  

  • 59. Herbal Highs: Review on Psychoactive Effects and Neuropharmacology.
    Graziano S; Orsolini L; Rotolo MC; Tittarelli R; Schifano F; Pichini S
    Curr Neuropharmacol; 2017; 15(5):750-761. PubMed ID: 27799032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.